Donoghue, Mark T. A.
Schram, Alison M.
Hyman, David M.
Taylor, Barry S.
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01 CA207244, P30 CA008748, U54 OD020355, R01 CA207244, R01 CA204749, R01 CA245069)
Article History
Received: 10 February 2020
Accepted: 15 July 2020
First Online: 10 August 2020
Competing interests
: D.M.H. reports receiving research funding from AstraZeneca, Puma Biotechnology, and Loxo Oncology, and personal fees from Atara Biotherapeutics, Chugai Pharma, Boehringer Ingelheim, AstraZeneca, Pfizer, Bayer, Debiopharm Group, and Genentech. B.S.T. reports receiving honoria and research funding from Genentech and Illumina and advisory board activities for Boehringer Ingelheim and Loxo Oncology, a wholly owned subsidiary of Eli Lilly.